Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Deepa Jagadeesh
Primary Objective • To determine overall response rate (CR+PR) of brentuximab vedotin in CD30 low (\<10%) relapsed or refractory T cell lymphoma (TCL) Secondary Objective(s) * Complete remission (CR) rate * Duration of response (DOR) * Progression free survival (PFS) * Overall survival (OS) * Time to treatment failure (TTF)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted